Immune responses of a liposome/ISCOM vaccine adjuvant against streptococcal fibronectin binding protein 1 (Sfb1) in mice

Indian Journal of Medical Research, Supplement

Volumn 119, Issue MAY, 2004, Pages 115-120

  McArthur, J ^a   Schulze, K ^d   Chin, J ^b   Currie, B J ^a,b,d   Sriprakash, K S ^a,b,c,d   Talay, S R ^e   Chhatwal, G S ^e   Guzman C A ^e   Walker, M J ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b NSW AGRICULTURE   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d University of Melbourne   (Australia)

^e HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Sfb1 liposome ISCOM vaccine adjuvant

Indexed keywords

CHOLERA TOXIN B SUBUNIT; FIBRONECTIN BINDING PROTEIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; ISCOM; LIPOSOME; STREPTOCOCCUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; CELL ASSAY; CELL COUNT; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MIXTURE; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; INOCULATION; LYMPHOCYTE PROLIFERATION; MOUSE; MOUSE STRAIN; NONHUMAN; PROVOCATION TEST; SPLEEN CELL; STREPTOCOCCUS; STREPTOCOCCUS PYOGENES; TREATMENT FAILURE; VACCINATION;

ADHESINS, BACTERIAL; ANIMALS; ANTIBODY FORMATION; BACTERIAL VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ISCOMS; LIPOSOMES; LYMPHOCYTES; MICE; MICE, INBRED BALB C; STREPTOCOCCUS PYOGENES;

EID: 3442889106     PISSN: 03679012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Molinari G, Talay SR, Valentin-Weigand P, Rohde M, Chhatwal GS. The fibronectin-binding protein of Streptococcus pyogenes, SfbI, is involved in the internalization of group A streptococci by epithelial cells. Infect Immun 1997; 65: 1357-63.
2. Talay SR, Valentin-Weigand P, Jerlstrom PG, Timmis KN, Chhatwal GS. Fibronectin-binding protein of Streptococcus pyogenes: sequence of the binding domain involved in adherence of streptococci to epithelial cells. Infect Immun 1992; 60: 3937-44.
3. Medina E, Molinari G, Rohde M, et al. Fc-mediated nonspecific binding between fibronectin-binding protein I of Streptococcus pyogenes and human immunoglobulins. J Immunol 1999; 163: 3396-402.
4. Courtney HS, Dale JB, Hasty DL. Strategies for preventing group A streptococcal adhesion and infection. In: An YH, Friedman RJ, editors. Handbook of bacterial adhesion: principles, methods and applications. Totowa, NJ: Humana Press Inc; 2000 p. 553-79.
5. Wizemann TM. Adamou JE, Langermann S. Adhesins as targets for vaccine development. Emerg Infect Dis 1999; 5: 395-403.
6. Guzman CA, Talay SR, Molinari G, Medina E, Chhatwal GS. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. J Infect Dis 1999; 179: 901-6.
7. Talay SR, Valentin-Weigand P, Timmis KN, Chhatwal GS. Domain structure and conserved epitopes of Sfb protein, the fibronectin- binding adhesin of Streptococcus pyogenes. Mol Microbiol 1994; 13: 531-9.
8. Valentin-Weigand P, Talay SR, Kaufhold A, Timmis KN, Chhatwal GS. The fibronectin binding domain of the Sfb protein adhesin of Streptococcus pyogenes occurs in many group A streptococci and does not cross-react with heart myosin. Microb Pathog 1994; 17: 111-20.
9. Kenney RT, Regina Rabinovich N, Pichyangkul S, Price VL, Engers HD. 2nd meeting on novel adjuvants currently in/close to human clinical testing. World Health Organization-Organization Mondiale de la Sante Fondation Merieux, Annecy, France, 5-7 June 2000. Vaccine 2002; 20: 2155-63.
10. Van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000; 165: 4778-82.
11. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002; 20: 2431-8.
12. Chin J, San Gil F, Novak M, et al. Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants. J Biotechnol 1996; 44: 13-9.
13. Walker MJ, Birch R, Pemberton JM. Cloning and characterisation of an albicidin resistance gene from Klebsiella oxytoca. Mol Microbiol 1988; 2: 443-54.
14. Sambrook J, Fritsch E, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbour Press; 1989.
15. Sjolander A, Drane D, Maraskovsky E, et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine 2001; 19: 2661-5.
16. O'Hagan DT, MacKichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 2001; 18: 69-85.
17. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000; 19: 1180-7.
18. San Gil F, Turner B, Walker MJ, Djordjevic SP, Chin JC. Contribution of adjuvant to adaptive immune responses in mice against Actinobacillus pleuropneumoniae. Microbiology 1999; 145: 2595-603.
19. San Gil F, Turner B, Mullbacher A, et al. Flow cytometric analysis of cellular changes in mice after intradermal inoculation with a liposome-iscom adjuvanted vaccine. Scand J Immunol 1998; 47: 243-53.
20. Schulze K, Medina E, Talay SR, et al. Characterization of the domain of fibronectin-binding protein I of Streptococcus pyogenes responsible for elicitation of a protective immune response. Infect Immun 2001; 69: 622-5.
21. Brandt ER, Hayman WA, Currie B, et al. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology 1996; 89: 331-7.
22. Watson DL, Lovgren K, Watson NA, et al. Inflammatory response and antigen localization following immunization with influenza virus ISCOMs. Inflammation 1989; 13: 641-9.
23. Fossum C, Bergstrom M, Lovgren K, Watson DL, Morein B. Effect of iscoms and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: comparison of spleen cells from mice inoculated with iscoms and/or matrix. Cell Immunol 1990; 129: 414-25.